1. Home
  2. RNTX vs GIFT Comparison

RNTX vs GIFT Comparison

Compare RNTX & GIFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.30

Market Cap

30.0M

Sector

Health Care

ML Signal

HOLD

Logo RDE Inc.

GIFT

RDE Inc.

HOLD

Current Price

$0.92

Market Cap

33.1M

ML Signal

HOLD

Company Overview

Basic Information
Metric
RNTX
GIFT
Founded
2001
1999
Country
United States
United States
Employees
11
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Catalog/Specialty Distribution
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
30.0M
33.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RNTX
GIFT
Price
$1.30
$0.92
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
94.8K
74.0K
Earning Date
05-14-2026
03-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$7.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.02
$0.73
52 Week High
$2.22
$2.38

Technical Indicators

Market Signals
Indicator
RNTX
GIFT
Relative Strength Index (RSI) 54.09 50.00
Support Level $1.06 $0.73
Resistance Level $1.30 $1.16
Average True Range (ATR) 0.12 0.10
MACD -0.00 0.02
Stochastic Oscillator 51.43 57.10

Price Performance

Historical Comparison
RNTX
GIFT

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

About GIFT RDE Inc.

Giftify Inc through its wholly-owned subsidiary, has been in the business of connecting digital consumers, businesses and communities with dining and merchant deal options throughout the United States. The company connects digital consumers, businesses, and communities offering dining and merchant deal options nationwide restaurants, and retailers to customers. The Company buys merchant gift cards from the general public and distributors at a discount and then resells them at a markup.

Share on Social Networks: